EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss

Marco Allinovi iD, Luca Malatesta iD, Tiziana Biagioli iD, Elisabetta Antonioli, Federico Perfetto iD

Antibodies · 03.07.2026 · 15 (4) · 57

DOI: 10.3390/antib15040057 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 03.07.2026. Verfasst von Marco Allinovi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, 50134 Florence, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Daratumumab, a human IgG1 monoclonal antibody targeting CD38, is widely used in multiple myeloma and AL amyloidosis. Despite its clinical success, many patients fail to achieve durable responses or relapse, underscoring the importance of understanding resistance mechanisms. Drawing on experience from other better-studied monoclonal antibodies, resistance to daratumumab can be categorized into four main mechanisms: (1) reduced CD38 expression on plasma cells; (2) increased expression of complement inhibitory proteins (CD55/CD59), impairing complement-mediated cytotoxicity; (3) reduced drug bioavailability due to urinary loss in non-selective nephrotic syndrome; and (4) the development of neutralizing anti-daratumumab antibodies. Anti-drug antibodies (ADAs) may represent a potential mechanism of treatment failure through effects on pharmacokinetics, efficacy, and safety, even in patients on daratumumab therapy. Seven different trials have tested anti-daratumumab antibodies. Among them, anti-daratumumab antibodies were identified in only 0–2.4% of patients, and only in a small portion of these has it been proven to be neutralizing. Overall, ADAs appear rare, but these findings are likely underestimated due to short follow-up and suboptimal timing of assessment. In conclusion, standardized ADA monitoring, particularly months after treatment interruption or in cases of inadequate response or infusion-related reactions, may improve patient management and therapeutic outcomes.

Schlagwörter

Stichwörter der Autor:innen

amyloidosisanti-daratumumab antibodiesanti-drug antibodiesdaratumumabdaratumumab resistancemultiple myeloma

Autor:innen und Institutionen

  • Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, 50134 Florence, Italy.
  • Tuscan Regional Amyloidosis Centre, Careggi University Hospital, 50134 Florence, Italy.
  • General Laboratory, Department of Diagnostics, Careggi University Hospital, 50134 Florence, Italy.
  • Haematology Unit, Careggi University Hospital, 50134 Florence, Italy.

ORCID-Profile: Marco Allinovi, Luca Malatesta, Tiziana Biagioli, Federico Perfetto

Zitieren

APA

Allinovi, M., Malatesta, L., Biagioli, T., Antonioli, E., & Perfetto, F. (2026). Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss. Antibodies, 15(4), 57. https://doi.org/10.3390/antib15040057

Vancouver

Allinovi M, Malatesta L, Biagioli T, Antonioli E, Perfetto F. Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss. Antibodies. 2026;15(4):57. doi:10.3390/antib15040057

BibTeX
@article{Allinovi2026,
  author = {Allinovi, Marco and Malatesta, Luca and Biagioli, Tiziana and Antonioli, Elisabetta and Perfetto, Federico},
  title = {Potential Mechanisms of Partial/Transient Response or Resistance to Daratumumab Therapy: A Focus on Anti-Daratumumab Antibodies and Urinary Daratumumab Loss},
  journal = {Antibodies},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {57},
  doi = {10.3390/antib15040057}
}
Kostenlos starten →